PONTE VEDRA BEACH, Fla., Oct 25, 2021— RedDress, a privately held U.S. and Israel-based wound care company, today announced that it will showcase its innovative wound solution, ActiGraft® System at the Symposium on Advanced Wound Care (SAWC) Fall from October 29th through October 31st in Las Vegas, NV.
The Symposium on Advanced Wound Care Fall meeting (SAWC Fall) serves as a forum to connect the entire wound care team—physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians—with the foremost experts in wound care to improve patient outcomes through education.
“We are looking forward to attending this year’s SAWC Fall meeting to highlight pivotal data on ActiGraft’s healing technology and efficacy in treating diabetic foot ulcers,” said Robert Mueller, General Manager of RedDress. “Diabetic foot ulcers are extremely challenging wounds to treat, even amongst the most experienced wound care teams. As shown by our data, we are confident that ActiGraft can provide relief to providers fighting to heal these difficult wounds and look forward to sharing this technology with fellow industry professionals.
At the conference, RedDress will feature two abstracts that detail the technology and efficacy of ActiGraft:
- The Efficacy of ActiGraft, an Autologous Blood Clot, in the Treatment of Diabetic Foot Ulcers – A Registry Trial
- Topically Applied Autologous Blood Clot: Proposed Mechanism of Action of Cellular and Tissue Based Therapy in Clinical Observation
Attendees can view RedDress’ posters on Saturday, October 30th from 8:00am – 4:00pm in the Julius Ballroom 12. To learn more about how ActiGraft is used to support healing and improve patient outcomes, visit the RedDress team at Booth 638.
About ActiGraft®
ActiGraft based on RedDress’ proprietary patented technology, is an FDA-cleared wound care solution that enables health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.
ActiGraft is intended for exuding cutaneous wounds. ActiGraft includes blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.
About RedDress
RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.
Press & Media Inquiries
Alessandra Lalli, RedDress
Investor Inquiries
Russell Lalli, RedDress
###
ActiGraft® is a registered trademark of RedDress Ltd.